| . | Pt–Ir tip (n = 227) . | Gold-tip (n = 236) . | P . |
|---|---|---|---|
| Mean age ± SD, year | 66 ± 11 | 66 ± 10 | 0.74 |
| Female, n (%) | 35 (15%) | 45 (19%) | 0.26 |
| Mean body surface ± SD, kg/m2 | 2.05 ± 0.21 | 2.03 ± 0.21 | 0.23 |
| Clinical AFL, n (%) | |||
| Counter-clockwise | 215 (95%) | 224 (95%) | 0.93 |
| Clockwise | 16 (7%) | 17 (7%) | 0.99 |
| Due to medication for AFB | 21 (9%) | 24 (10%) | 0.75 |
| Pre-ablation history of AFB, n (%) | 89 (39%) | 88 (37%) | 0.87 |
| Mean LAEDD ± SD, mm | 45 ± 7 | 44 ± 6 | 0.14 |
| Mean LVEF ± SD, % | 51 ± 14 | 53 ± 15 | 0.16 |
| Structural heart disease, n (%) | 102 (45%) | 97 (41%) | 40 |
| Coronary artery disease | 62 (27%) | 56 (24%) | 0.84 |
| Dilated cardiomyopathy | 9 (4%) | 11 (5%) | 0.53 |
| Left heart hypertrophy | 30 (13%) | 29 (12%) | 0.89 |
| Valvular disease | 39 (17%) | 31 (13%) | 0.23 |
| Hypertension, n (%) | 122 (54%) | 123 (52%) | 0.23 |
| Pulmonary hypertension, n (%) | 14 (6%) | 6 (3%) | 0.09 |
| Chronic obstructive pulmonary disease, n (%) | 11 (5%) | 5 (2%) | 0.11 |
| Diabetes, n (%) | 20 (9%) | 34 (14%) | 0.06 |
| Antiarrhythmics, n (%) | 198 (87%) | 203 (86%) | 0.74 |
| Anticoagulants, n (%) | 188 (83%) | 178 (75%) | 0.06 |
| . | Pt–Ir tip (n = 227) . | Gold-tip (n = 236) . | P . |
|---|---|---|---|
| Mean age ± SD, year | 66 ± 11 | 66 ± 10 | 0.74 |
| Female, n (%) | 35 (15%) | 45 (19%) | 0.26 |
| Mean body surface ± SD, kg/m2 | 2.05 ± 0.21 | 2.03 ± 0.21 | 0.23 |
| Clinical AFL, n (%) | |||
| Counter-clockwise | 215 (95%) | 224 (95%) | 0.93 |
| Clockwise | 16 (7%) | 17 (7%) | 0.99 |
| Due to medication for AFB | 21 (9%) | 24 (10%) | 0.75 |
| Pre-ablation history of AFB, n (%) | 89 (39%) | 88 (37%) | 0.87 |
| Mean LAEDD ± SD, mm | 45 ± 7 | 44 ± 6 | 0.14 |
| Mean LVEF ± SD, % | 51 ± 14 | 53 ± 15 | 0.16 |
| Structural heart disease, n (%) | 102 (45%) | 97 (41%) | 40 |
| Coronary artery disease | 62 (27%) | 56 (24%) | 0.84 |
| Dilated cardiomyopathy | 9 (4%) | 11 (5%) | 0.53 |
| Left heart hypertrophy | 30 (13%) | 29 (12%) | 0.89 |
| Valvular disease | 39 (17%) | 31 (13%) | 0.23 |
| Hypertension, n (%) | 122 (54%) | 123 (52%) | 0.23 |
| Pulmonary hypertension, n (%) | 14 (6%) | 6 (3%) | 0.09 |
| Chronic obstructive pulmonary disease, n (%) | 11 (5%) | 5 (2%) | 0.11 |
| Diabetes, n (%) | 20 (9%) | 34 (14%) | 0.06 |
| Antiarrhythmics, n (%) | 198 (87%) | 203 (86%) | 0.74 |
| Anticoagulants, n (%) | 188 (83%) | 178 (75%) | 0.06 |
AFB, atrial fibrillation; AFL, atrial flutter; LAEDD, left atrial end-diastolic diameter; LVEF, left ventricular ejection fraction; Pt–Ir, platinum–iridium.
| . | Pt–Ir tip (n = 227) . | Gold-tip (n = 236) . | P . |
|---|---|---|---|
| Mean age ± SD, year | 66 ± 11 | 66 ± 10 | 0.74 |
| Female, n (%) | 35 (15%) | 45 (19%) | 0.26 |
| Mean body surface ± SD, kg/m2 | 2.05 ± 0.21 | 2.03 ± 0.21 | 0.23 |
| Clinical AFL, n (%) | |||
| Counter-clockwise | 215 (95%) | 224 (95%) | 0.93 |
| Clockwise | 16 (7%) | 17 (7%) | 0.99 |
| Due to medication for AFB | 21 (9%) | 24 (10%) | 0.75 |
| Pre-ablation history of AFB, n (%) | 89 (39%) | 88 (37%) | 0.87 |
| Mean LAEDD ± SD, mm | 45 ± 7 | 44 ± 6 | 0.14 |
| Mean LVEF ± SD, % | 51 ± 14 | 53 ± 15 | 0.16 |
| Structural heart disease, n (%) | 102 (45%) | 97 (41%) | 40 |
| Coronary artery disease | 62 (27%) | 56 (24%) | 0.84 |
| Dilated cardiomyopathy | 9 (4%) | 11 (5%) | 0.53 |
| Left heart hypertrophy | 30 (13%) | 29 (12%) | 0.89 |
| Valvular disease | 39 (17%) | 31 (13%) | 0.23 |
| Hypertension, n (%) | 122 (54%) | 123 (52%) | 0.23 |
| Pulmonary hypertension, n (%) | 14 (6%) | 6 (3%) | 0.09 |
| Chronic obstructive pulmonary disease, n (%) | 11 (5%) | 5 (2%) | 0.11 |
| Diabetes, n (%) | 20 (9%) | 34 (14%) | 0.06 |
| Antiarrhythmics, n (%) | 198 (87%) | 203 (86%) | 0.74 |
| Anticoagulants, n (%) | 188 (83%) | 178 (75%) | 0.06 |
| . | Pt–Ir tip (n = 227) . | Gold-tip (n = 236) . | P . |
|---|---|---|---|
| Mean age ± SD, year | 66 ± 11 | 66 ± 10 | 0.74 |
| Female, n (%) | 35 (15%) | 45 (19%) | 0.26 |
| Mean body surface ± SD, kg/m2 | 2.05 ± 0.21 | 2.03 ± 0.21 | 0.23 |
| Clinical AFL, n (%) | |||
| Counter-clockwise | 215 (95%) | 224 (95%) | 0.93 |
| Clockwise | 16 (7%) | 17 (7%) | 0.99 |
| Due to medication for AFB | 21 (9%) | 24 (10%) | 0.75 |
| Pre-ablation history of AFB, n (%) | 89 (39%) | 88 (37%) | 0.87 |
| Mean LAEDD ± SD, mm | 45 ± 7 | 44 ± 6 | 0.14 |
| Mean LVEF ± SD, % | 51 ± 14 | 53 ± 15 | 0.16 |
| Structural heart disease, n (%) | 102 (45%) | 97 (41%) | 40 |
| Coronary artery disease | 62 (27%) | 56 (24%) | 0.84 |
| Dilated cardiomyopathy | 9 (4%) | 11 (5%) | 0.53 |
| Left heart hypertrophy | 30 (13%) | 29 (12%) | 0.89 |
| Valvular disease | 39 (17%) | 31 (13%) | 0.23 |
| Hypertension, n (%) | 122 (54%) | 123 (52%) | 0.23 |
| Pulmonary hypertension, n (%) | 14 (6%) | 6 (3%) | 0.09 |
| Chronic obstructive pulmonary disease, n (%) | 11 (5%) | 5 (2%) | 0.11 |
| Diabetes, n (%) | 20 (9%) | 34 (14%) | 0.06 |
| Antiarrhythmics, n (%) | 198 (87%) | 203 (86%) | 0.74 |
| Anticoagulants, n (%) | 188 (83%) | 178 (75%) | 0.06 |
AFB, atrial fibrillation; AFL, atrial flutter; LAEDD, left atrial end-diastolic diameter; LVEF, left ventricular ejection fraction; Pt–Ir, platinum–iridium.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
